nach oben

Erschienen in:

2020 | OriginalPaper | Buchkapitel

6. Hemmstoffe des Renin-Angiotensin-Systems

verfasst von : Prof. Dr. med. Franz Weber, Prof. Dr. med. Manfred Anlauf

Erschienen in: Arzneiverordnungs-Report 2020

Verlag: Springer Berlin Heidelberg

Einloggen, um Zugang zu erhalten

Zusammenfassung

Auf einen Blick

Verordnungsprofil Hemmstoffe des Renin-Angiotensin-Systems (RAS) gehören zu den erfolgreichsten Arzneimitteln zur Behandlung von Hypertonie, Herz- und Nierenkrankheiten. ACE-Hemmer dominieren weiterhin die Substanzgruppe, steigern ihren Marktanteil jedoch nur gering im Vergleich zum Vorjahr (1,5 %), während Angiotensinrezeptorantagonisten große Gewinne verbuchen (10,8 %).

Trend Die Verordnungen der Hemmstoffe des Renin-Angiotensin-Systems waren zusammen so hoch, dass sie 59,3 % des Verordnungsvolumens der Antihypertensiva ausmachen. Die günstigsten Tagestherapiekosten für Monopräparate haben weiterhin die ACE-Hemmer (0,05 €), deutlich höher liegen Sartane (0,10 €).

Bewertung ACE-Hemmer und Sartane werden nach aktuellen Leitlinien als Mittel der Wahl zur antihypertensiven Therapie empfohlen. Eine Überlegenheit der Angiotensinrezeptorantagonisten im Vergleich zu ACE-Hemmern ist bei den unerwünschten Wirkungen (insbesondere Husten und Angioödem) belegt, für die Verhinderung koronarer Ereignisse deutet sich in kontrollierten Studien eine leichte Unterlegenheit, bei der Vermeidung zerebraler Ereignisse eine geringe Überlegenheit an. Eine Kombination von ACE-Hemmern und Angiotensinrezeptorantagonisten wird von der EMA wegen besonderer Gefahren nicht empfohlen.

Anlauf M, Weber F (2015) Hemmstoffe des Renin-Angiotensin-Systems. In: Schwabe U, Paffrath D (Hrsg) Arzneiverordnungs-Report, Bd. 2015. Springer, Berlin Heidelberg, S 267–309

Arzneimittelkommission der Deutschen Ärzteschaft (2004) Empfehlungen zur Therapie der arteriellen Hypertonie, 2. Aufl. Arzneiverordnung in der Praxis, Bd. 31 (Sonderheft 2 (Therapieempfehlungen))

Aygören-Pürsün E, Magerl M, Maetzel A, Maurer M (2018) Epidemiology of Bradykinin-mediated angioedema: a systematic investigation of epidemiological studies. Orphanet J Rare Dis 13:73. https://doi.org/10.1186/s13023-018-0815-5 PubMedPubMedCentralCrossRef

Bakris GL, Sarafidis PA, Weir MR, Dahlöf B, Pitt B, Jamerson K, Velazquez EJ, Staikos-Byrne L, Kelly RY, Shi V, Chiang YT, Weber MA, ACCOMPLISH Trial investigators (2010) Renal outcomes with diff erent fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 375:1173–1181PubMed

Bangalore S, Kumar S, Wetterslev J, Messerli FH (2011) Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial sequential analyses of 147 020 patients from randomised trials. BMJ 342:d2234PubMedPubMedCentral

Bangalore S, Kumar S, Messerli FH (2013) When conventional heart failure therapy is not enough: angiotensin receptor blocker, direct renin inhibitor, or aldosterone antagonist? Congest Heart Fail 19:107–115PubMed

Bangalore S, Fakheri R, Wandel S, Toklu B, Wandel J, Messerli FH (2017) Renin angiotensin system inhibitors for patients with stable coronary artery disease without heart failure: systematic review and meta-analysis of randomized trials. BMJ 356:j4. https://doi.org/10.1136/bmj.j4 PubMedPubMedCentralCrossRef

Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, Mustonen J, Diabetics Exposed to Telmisartan and Enalapril Study Group (2004) Angiotensin-receptor blockade versus converting–enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 351:1952–1961PubMed

Beckett N, Peters R, Tuomilehto J, Swift C, Sever P, Potter J, McCormack T, Forette F, Gil-Extremera B, Dumitrascu D, Staessen JA, Thijs L, Fletcher Bulpitt AC, HYVET Study Group (2012) Immediate and late benefits of treating very elderly people with hypertension: results from active treatment extension to Hypertension in the Very Elderly randomised controlled trial. BMJ 344:1–10

Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, Stoyanovsky V, Antikainen RL, Nikitin Y, Anderson C, Belhani A, Forette F, Rajkumar C, Thijs L, Banya W, Bulpitt CJ, HYVET Study Group (2008) Treatment of hypertension in patients 80 years of age or older. N Engl J Med 358:1887–1898PubMed

Berrido AM, Byrd JB (2020) Angiotensin receptor blockers and the risk of cancer: Insights from clinical trials and recent drug recalls. Curr Hypertens Rep. https://doi.org/10.1007/s11906-020-1021-0 PubMedCrossRef

Blood Pressure Lowering Treatment Trialists’ Collaboration (2000) Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 356:1955–1964

Blood Pressure Lowering Treatment Trialists’ Collaboration (2007) Blood pressure dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens 25:951–958

Blood Pressure Lowering Treatment Trialists’ Collaboration (2015) Effects of blood pressure lowering on cardiovascular risk according to baseline body-mass index: a meta-analysis of randomised trials. Lancet 385:867–874

Bundesärztekammer, Kassenärztliche Bundesvereinigung, Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (2011) Nationale VersorgungsLeitlinie Nierenerkrankungen bei Diabetes im Erwachsenenalter, 1. Aufl. (Version 1.3)

Byrne C, Pareek M, Vaduganathan M, Biering-Sørensen T, Qamar A, Pandey A, Olesen TB, Olsen MH, Bhatt DL (2019) Intensive blood pressure lowering in different age categories: insights from the Systolic Blood Pressure Intervention Trial. Eur Heart J Cardiovasc Pharmacother. https://doi.org/10.1093/ehjcvp/pvz050 CrossRefPubMedCentral

Chang CH, Chang YC, Wu LC, Lin JW, Chuang LM, Lai MS (2014) Different angiotensin receptor blockers and incidence of diabetes: a nationwide population-based cohort study. Cardiovasc Diabetol 13:91PubMedPubMedCentral

Cheng J, Zhang W, Zhang X, Han F, Li X, He X, Li Q, Chen J (2014) Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis. JAMA Intern Med 174:773–785PubMed

Czernichow S, Zanchetti A, Turnbull F, Barzi F, Ninomiya T, Kengne AP, Lambers Heerspink HJ, Perkovic V, Huxley R, Arima H, Patel A, Chalmers J, Woodward M, MacMahon S, Neal B (2011) The effects of blood pressure reduction and of different blood pressure-lowering regimens on major cardiovascular events according to baseline blood pressure: meta-analysis of randomized trials. J Hypertens 29:4–16PubMed

Datzmann T, Fuchs S, Andree D, Hohenstein B, Schmitt J, Schindler C (2019) Systematic review and meta-analysis of randomised controlled clinical trial evidence refutes relationship between pharmacotherapy with angiotensin-receptor blockers and an increased risk of cancer. Eur J Intern Med 64:1–9PubMed

Dickstein K, Kjekshus J, the OPTIMAAL Steering Committee, the OPTIMAAL Study Group (2002) Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet 360:752–760PubMed

Elliott WJ, Meyer PM (2007) Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 369:201–207PubMed

Emdin CA, Rahimi K, Neal B, Callender T, Perkovic V, Patel A (2015) Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA 313:603–615PubMed

Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, Chalmers J, Rodgers A, Rahimi K (2016) Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 387:957–967PubMed

FDA Drug Safety Communication (2013) FDA approves label changes to include intestinal problems (sprue-like enteropathy) linked to blood pressure medicine olmesartan medoxomil. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-approves-label-changes-include-intestinal-problems-sprue

Flather MD, Yusuf S, Kober L, Pfeffer M, Hall A, Murray G, Torp-Pedersen C, Ball S, Pogue J, Moyé L, Braunwald E (2000) Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. Lancet 355:1575–1581PubMed

Flint AC, Conell C, Ren X, Banki NM, Chan SL, Rao VA, Melles RB, Deepak L, Bhatt DL (2019) Effect of systolic and diastolic blood pressure on cardiovascular outcomes. N Engl J Med 381:243–251PubMed

Gandhi S, Fleet JL, Bailey DG, McArthur E, Wald R, Rehman F, Garg AX (2013) Calcium-channel blocker-clarithromycin drug interactions and acute kidney injury. JAMA 310:2544–2553PubMed

Granger CB, McMurray JJV, Yusuf S, Held P, Michelson EL, Olofsson B, Ostergren J, Pfeffer MA, Swedberg K, CHARM Investigators (2003) Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 362:772–776PubMed

Hasenfuss G, Edelmann F, Wachter R (2013) Empfehlung zur Herzinsuffizienz Was gibt es Neues? Internist 54:1141–1151PubMed

Hausberg M, Trenkwalder P, Weisser B, Krämer BK (2019) Antihypertensiva: Verunsicherung durch potenziell gravierende Nebenwirkungen. Dtsch Arztebl 116:A366–A370

Heerspink HL, de Zeeuw D (2010) Composite renal endpoints: was ACCOMPLISH accomplished? Lancet 375:1140–1142PubMed

Heerspink HJ, Ninomiya T, Perkovic V, Woodward M, Zoungas S, Cass A, Cooper M, Grobbee DE, Mancia G, Mogensen CE, Neal B, Chalmers J, ADVANCE Collaborative Group (2010) Effects of a fixed combination of perindopril and indapamide in patients with type 2 diabetes and chronic kidney disease. Eur Heart J 31:2888–2896PubMed

Hicks BM, Filion KB, Yin H, Sakr L, Udell JA, Azoulay L (2018) Angiotensin converting enzyme inhibitors and risk of lung cancer: population based cohort study. BMJ 363:k4209PubMedPubMedCentral

Huang Y, Su L, Cai X, Mai W, Wang S, Hu Y, Wu Y, Tang H, Xu D (2014) Association of all-cause and cardiovascular mortality with prehypertension: a meta-analysis. Am Heart J 167:160–168PubMed

Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V, Hester A, Gupte J, Gatlin M, Velazquez EJ, ACCOMPLISH Trial Investigators (2008) Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 359(23):2417–2428PubMed

Jamerson KA, Devereux R, Bakris GL, Dahlöf B, Pitt B, Velazquez EJ, Weir M, Kelly RY, Hua TA, Hester A, Weber MA (2011) Efficacy and duration of benazepril plus amlodipine or hydrochlorothiazide on 24-hour ambulatory systolic blood pressure control. Hypertension 57:174–179PubMed

Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A, VALUE trial group (2004) Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363:2022–2031PubMed

Julius S, Nesbitt SD, Egan BM, Trial of Preventing Hypertension (TROPHY) Study Investigators (2006) Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 354:1685–1697PubMed

Konstam MA, Neaton JD, Dickstein K, Drexler H, Komajda M, Martinez FA, Riegger GA, Malbecq W, Smith RD, Guptha S, Poole-Wilson PA, HEAAL Investigators (2009) Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet 374:1840–1848PubMed

Kunz R, Friedrich C, Wolbers M, Mann JFE (2008) Meta-analysis: Effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 148:30–48PubMed

Lin SY, Lin CL, Lin CC, Hsu WH, Lin CD, Wang IK, Hsu CY, Kao CH (2020) Association between Angiotensin-converting enzyme inhibitors and lung cancer - A nationwide, population-based, propensity score-matched cohort study. Cancers 12(3):747. https://doi.org/10.3390/cancers12030747 PubMedCentralCrossRef

Lonn EM, Bosch J, López-Jaramillo P, Zhu J, Liu L, Pais P, Diaz R, Xavier D, Sliwa K, Dans A, Avezum A, Piegas LS, Keltai K, Keltai M, Chazova I, Peters RJ, Held C, Yusoff K, Lewis BS, Jansky P, Parkhomenko A, Khunti K, Toff WD, Reid CM, Varigos J, Leiter LA, Molina DI, McKelvie R, Pogue J, Wilkinson J, Jung H, Dagenais G, Yusuf S, HOPE-3 Investigators (2016) Blood-pressure lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med 374:2009–2020PubMed

Lüders S, Schrader J, Berger J, Unger T, Zidek W, Böhm M, Middeke M, Motz W, Lübcke C, Gansz A, Brokamp L, Schmieder RE, Trenkwalder P, Haller H, Dominiak P, PHARAO study group (2008) The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure – a prospective, randomized, controlled prevention trial of the German Hypertension League. J Hypertens 26:1487–1496PubMed

Lv J, Ehteshami P, Sarnak MJ, Tighiouart H, Jun M, Ninomiya T, Foote C, Rodgers A, Zhang H, Wang H, Strippoli GF, Perkovic V (2013) Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis. Cmaj 185:949–957PubMedPubMedCentral

Lv Y, Zou Z, Chen GM, Jia HX, Zhong J, Fang WW (2010) Amlodipine and angiotensin-converting enzyme inhibitor combination versus amlodipine monotherapy in hypertension: a meta-analysis of randomized controlled trials. Blood Press Monit 15:195–204PubMed

Malacco E, Santonastaso M, Vari NA, Gargiulo A, Spagnuolo V, Bertocchi F, Palatini P, Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril Study (2004) Comparison of valsartan 160 mg with lisinopril 20 mg, given as monotherapy or in combination with a diuretic, for the treatment of hypertension: the Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril (PREVAIL) study. Clin Ther 26:855–865PubMed

Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, Chaithiraphan S, Dickstein K, Keltai M, Metsärinne K, Oto A, Parkhomenko A, Piegas LS, Svendsen TL, Teo KK, Yusuf S, ONTARGET investigators (2008) Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 372:547–553PubMed

McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, PARADIGM-HF Investigators and Committees (2014) Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371:993–1004PubMed

McMurray JJ, Krum H, Abraham WT et al (2016) Aliskiren, enalapril, or aliskiren and enalapril in heart failure. N Engl J Med 374:1521–1532PubMed

Messerli FH, Bangalore S, Bavishi C, Rimoldi SF (2018) Angiotensin-converting enzyme inhibitors in hypertension: to use or not to use? J Am Coll Cardiol 71:1474–1482PubMed

National Collaborating Centre for Chronic Conditions (2006) Hypertension: management of hypertension in adults in primary care: partial update. http://guidance.nice.org.uk/CG34/guidance/pdf/English (Royal College of Physicians, London)

NICE guideline (2019) Hypertension in adults: diagnosis and management. www.nice.org.uk/guidance/ng136. Zugegriffen: 28. Aug. 2019

Nicholls SJ, Bakris GL, Kastelein JJ, Menon V, Williams B, Armbrecht J, Brunel P, Nicolaides M, Hsu A, Hu B, Fang H, Puri R, Uno K, Kataoka Y, Bash D, Nissen SE (2013) Effect of aliskiren on progression of coronary disease in patients with prehypertension: the AQUARIUS randomized clinical trial. JAMA 310:1135–1144PubMed

Padwal R, Lin M, Etminan M, Eurich DT (2014) Comparative effectiveness of olmesartan and other angiotensin receptor blockers in diabetes mellitus: retrospective cohort study. Hypertension 63:977–983PubMed

Palmer SC, Mavridis D, Navarese E, Craig JC, Tonelli M, Salanti G, Wiebe N, Ruospo M, Wheeler DC, Strippoli GF (2015) Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis. Lancet 385:2047–2056PubMed

Pierre-Louis B, Rodriques S, Gorospe V, Guddati AK, Aronow WS, Ahn C, Wright M (2016) Clinical factors associated with early readmission among acutely decompensated heart failure patients. Arch Med Sci 12:538–545PubMedPubMedCentral

Pitt B (2004) ACE inhibitors for patients with vascular disease without left ventricular dysfunction – may they rest in PEACE? N Engl J Med 351:2115–2117PubMed

Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, Konstam MA, Riegger G, Klinger GH, Neaton J, Sharma D, Thiyagarajan B (2000) Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial – the Losartan Heart Failure Survival Study ELITE II. Lancet 355:1582–1587PubMed

Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P, Authors/Task Force Members Document Reviewers (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 18:891–975PubMed

Potier L, Roussel R, Elbez Y, Marre M, Zeymer U, Reid CM, Ohman M, Eagle KA, Bhatt DL, Steg PG, REACH Registry Investigators (2017) Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in high vascular risk. Heart 103:1339–1346PubMed

Qiao Y, Shin JI, Teresa K, Chen TK, Inker LA, Coresh J, Alexander GC, Jackson JW, Chang AR, Grams ME (2020) Association Between Renin-Angiotensin System Blockade Discontinuation and All-Cause Mortality Among Persons With LowEstimated Glomerular Filtration Rate. JAMA Intern Med. https://doi.org/10.1001/jamainternmed.2020.0193 PubMedCrossRefPubMedCentral

Rubio-Tapia A, Herman ML, Ludvigsson JF, Kelly DG, Mangan TF, Wu TT, Murray JA (2012) Severe spruelike enteropathy associated with olmesartan. Mayo Clin Proc 87:732–738PubMedPubMedCentral

Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, Rubis N, Gherardi G, Arnoldi F, Ganeva M, Ene-Iordache B, Gaspari F, Perna A, Bossi A, Trevisan R, Dodesini AR, Remuzzi G, Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators (2004) Preventing microalbuminuria in type 2 diabetes. N Engl J Med 351:1941–1951PubMed

Saglimbene V, Palmer SC, Ruospo M et al (2018) The long-term impact of renin-angiotensin system (RAS) inhibition on cardiorenal outcomes (LIRICO): a randomized, controlled trial. J Am Soc Nephrol 29:2890–2899PubMedPubMedCentral

Sanchis-Gomar F, Carl J, Lavie CJ, Perez-Quilis C, Brandon MH, Lippi G (2020) Angiotensin-Converting Enzyme 2 and Antihypertensives (Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors) in Coronavirus Disease 2019. Proc. https://doi.org/10.1016/j.mayocp.2020.03.026 CrossRef

Sandset EC, Bath PM, Boysen G, Jatuzis D, Kõrv J, Lüders S, Murray GD, Richter PS, Roine RO, Terént A, Thijs V, Berge E, SCAST Study Group (2011) The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial. Lancet 377:741–750PubMed

Sato A, Fukuda S (2015) A prospective study of frequency and characteristics of cough during ACE inhibitor treatment. Clin Exp Hypertens 37:563–568PubMed

Schmidt SA, Schmidt M, Mehnert F, Lemeshow S, Sorensen HT (2015) Use of antihypertensive drugs and risk of skin cancer. J Eur Acad Dermatol Venereol 29:1545–1554PubMed

Schmieder RE, Hilgers KF, Schlaich MP, Schmidt MW (2007) Renin angiotensin system and cardiovascular risk. Lancet 369:1208–1219PubMed

Schneider MP, Hua TA, Böhm M, Wachtell K, Kjeldsen SE, Schmieder RE (2010) Prevention of atrial fibrillation by Renin-Angiotensin system inhibition a meta-analysis. J Am Coll Cardiol 55:2299–2307PubMed

Schrader J, Luders S, Kulschewski A, Berger J, Zidek W, Treib J, Einhäupl K, Diener HC, Dominiak P, Acute Candesartan Cilexetil Therapy in Stroke Survivors Study Group (2003) The ACCESS study: evaluation of acute candesartan cilexetil therapy in stroke survivors. Stroke 234:1699–1703

Schrader J, Lüders S, Kulschewski A, Hammersen F, Plate K, Berger J, Zidek W, Dominiak P, Diener HC, MOSES Study Group (2005) Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention. Principal results of a prospective randomized controlled study (MOSES). Stroke 36:1218–1226PubMed

Smith L, Parris C, Veronese N, Shang C, Lopez-Sanchez GF, Jacob L, Koyanagi A, Nottegar A, Jackson SE, Raupach T, Grabovac I, Crichton S, Dempsey F, Yang L (2020) Cross-sectional associations between angiotensin-converting enzyme inhibitor use and cancer diagnosis in US adults. Clin Exp Med. https://doi.org/10.1007/s10238-020-00622-7 PubMedCrossRef

Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, van Veldhuisen DJ, Zannad F, Zile MR, Desai AS, Claggett B, Jhund PS, Boytsov SA, Comin-Colet J, Cleland J, Dungen HD, Goncalvesova E, Katova T, Kerr Saraiva JF, Lelonek M, Merkely B, Senni M, Shah SJ, Zhou J, Rizkala AR, Gong J, Shi VC, Lefkowitz MP, Paragon-Hf Investigators Committees (2019) Angiotensin–neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med 381:1609–1620PubMed

Staessen JA, Li Y, Thijs L, Wang JG (2005) Blood pressure reduction and cardiovascular prevention: an update including the 2003–2004 secondary prevention trials. Hypertens Res 28:385–407PubMed

Stiles S (2018) Old Age and ACE inhibitors in heart failure: cohort study tries to bridge guidelines gap – Medscape

Suchard MA, Schuemie MJ, Krumholz HM, You SC, Chen R, Pratt N, Reich CG, Duke J, Madigan D, Hripcsak G, Ryan PB (2019) Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis. Lancet 394:1816–1826PubMedPubMedCentral

Svensson P, de Faire U, Sleight P, Yusuf S, Östergren JJ (2001) Comparative effects of ramipril on ambulatory and office blood pressures. A HOPE substudy. Hypertension 38:e28–e32PubMed

Tamargo J (2019) Sodium–glucose cotransporter 2 inhibitors in heart failure: potential mechanisms of action, adverse effects and future developments. Eur Cardiol Rev 14:23–32

The ACTIVE I Investigators (2011) Irbesartan in patients with atrial fibrillation. N Engl J Med 364:928–938

The EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators (2003) Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 362:782–788

The GISSI-AF Investigators (2009) Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med 360:1606–1617

The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators (2000) Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342:145–153

The ONTARGET Investigators (2008) Telmisartan, ramipril or both in patients at high risk for vascular events. N Engl J Med 358:1547–1559

The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) (2018) 2018 ESC/ESH Guidelines for the management of arterial hypertension. J Hypertens 36:1953–2041

The Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators (2008) Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 372:1174–1183

Thomopoulos C, Parati G, Zanchetti A (2017a) Effects of blood-pressure-lowering treatment on outcome incidence in hypertension. 11. Effects of total cardiovascular risk and achieved blood pressure: overview and meta-analyses of randomized trials. J Hypertens 35:2138–2149PubMed

Thomopoulos C, Parati G, Zanchetti A (2017b) Effects of blood-pressure-lowering treatment on outcome incidence in hypertension: 10 – Should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials. J Hypertens 35:922–944PubMed

Thomopoulos C, Parati G, Zanchetti A (2017c) Effects of blood-pressure-lowering treatment on outcome incidence. 12. Effects in individuals with high-normal and normal blood pressure: overview and meta-analyses of randomized trials. J Hypertens 35:2150–2160PubMed

Thomopoulos C, Parati G, Zanchetti A (2018a) Effects of blood pressure-lowering treatment on cardiovascular outcomes and mortality: 13 – benefits and adverse events in older and younger patients with hypertension: overview, meta-analyses and meta-regression analyses of randomized trials. J Hypertens 36:1622–1636PubMed

Thomopoulos C, Parati G, Zanchetti A (2018b) Effects of blood pressure-lowering treatment on cardiovascular outcomes and mortality: 14 – effects of different classes of antihypertensive drugs in older and younger patients: overview and meta-analysis. J Hypertens 36:1637–1647PubMed

Thompson AM, Hu T, Eshelbrenner CL, Reynolds K, He J, Bazzano LA (2011) Antihypertensive treatment and secondary prevention of cardiovascular disease events among persons without hypertension: a meta-analysis. JAMA 305:913–922PubMedPubMedCentral

Tsimploulis A, Lam PH, Arundel C, Singh SN, Morgan CJ, Faselis C, Deedwania P, Butler J, Aronow WS, Yancy CW, Fonarow GC, Ahmed A (2018) Systolic blood pressure and outcomes in patients with heart failure with preserved ejection fraction. JAMA Cardiol 3:288–297PubMedPubMedCentral

Verma S, Strauss M (2004) Angiotensin receptor blockers and myocardial infarction. These drugs may increase myocardial infarction – and patients may need to be told. BMJ 329:1248–1249PubMedPubMedCentral

Vidal-Petiot E, Sorbets E, Bhatt DL et al (2018) Potential impact of the 2017 ACC/AHA guideline on high blood pressure in normotensive patients with stable coronary artery disease: insights from the CLARIFY registry. Eur Heart J 39:3855–3863PubMedPubMedCentral

Wachtell K, Hornestam B, Lehto M, Slotwiner DJ, Gerdts E, Olsen MH, Aurup P, Dahlöf B, Ibsen H, Julius S, Kjeldsen SE, Lindholm LH, Nieminen MS, Rokkedal J, Devereux RB (2005a) Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 45:705–711PubMed

Wachtell K, Lehto M, Gerdts E, Olsen MH, Hornestam B, Dahlöf B, Ibsen H, Julius S, Kjeldsen SE, Lindholm LH, Nieminen MS, Devereux RB (2005b) Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 45:712–719PubMed

Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, Zinman B (2016) Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375:323–334PubMed

Weber F, Anlauf M (2019) Hemmstoffe des Renin-Angiotensin-Systems. In: Schwabe U, Paffrath D, Ludwig WD, Klauber J (Hrsg) Arzneiverordnungs-Report. Springer, Berlin, Heidelberg, S 359–388

Weber MA, Jamerson K, Bakris GL, Weir MR, Zappe D, Zhang Y, Dahlof B, Velazquez EJ, Pitt B (2013) Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial. Lancet 381:537–545PubMed

Whelton PK, Carey RM (2018) The 2017 American College of Cardiology/American Heart Association Clinical Practice Guideline for high blood pressure in adults. JAMA Cardiol 3:352–353PubMed

Williamson JD, Supiano MA, Applegate WB, Berlowitz DR, Campbell RC, Chertow GM, Fine LJ, Haley WE, Hawfield AT, Ix JH, Kitzman DW, Kostis JB, Krousel-Wood MA, Launer LJ, Oparil S, Rodriguez CJ, Roumie CL, Shorr RI, Sink KM, Wadley VG, Whelton PK, Whittle J, Woolard NF, Wright JT Jr, Pajewski NM, SPRINT Research Group (2016) Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged ≥ 75 years: a randomized clinical trial. JAMA 315:2673–2682PubMedPubMedCentral

Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, Drazner MH, Filippatos GS, Fonarow GC, Givertz MM, Hollenberg SM, Lindenfeld J, Masoudi FA, McBride PE, Peterson PN, Stevenson LW, Westlake C (2017) 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol 70:776–803PubMed

Yang R, Luo Z, Liu Y, Sun M, Zheng L, Chen Y, Li Y, Wang H, Chen L, Wu M, Zhao H (2016) Drug interactions with angiotensin receptor blockers: role of human cytochromes P450. Curr Drug Metab 17:681–691PubMed

Yusuf S (2002) From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis. Am J Cardiol 89:18A–25APubMed

Yusuf S, Diener HC, Sacco RL, Cotton D, Ôunpuu S for the PRoFESS Study Group (2008) Telmisartan to prevent recurrent stroke and cardiovascular Events. N Engl J Med 359:1225–1237PubMedPubMedCentral

Zelniker TA, Wiviott SD, Raz I et al (2019) SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 393:31–39PubMed

Titel: Hemmstoffe des Renin-Angiotensin-Systems
verfasst von: Prof. Dr. med. Franz Weber
Prof. Dr. med. Manfred Anlauf
Verlag: Springer Berlin Heidelberg
Buch: Arzneiverordnungs-Report 2020
Print ISBN: 978-3-662-62167-7

Electronic ISBN: 978-3-662-62168-4

Copyright-Jahr: 2020
DOI: https://doi.org/10.1007/978-3-662-62168-4_6

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen